AB-103

Last updated

AB-103
Clinical data
Other namesAB103
Routes of
administration 		Topical [1]
Drug class Minoxidil sulfotransferase stimulant

AB-103 is a minoxidil sulfotransferase stimulant which is under development for the treatment of alopecia (hair loss) as an adjunct to the hair loss drug minoxidil. [1] It is used topically. [1] The drug works by stimulating the enzyme SULT1A1 in hair follicles which converts minoxidil into its active form minoxidil sulfate and which has been found to predict minoxidil's clinical effectiveness. [1] [2] [3] [4] It was originated by Applied Biology and is under development by Safety Shot. [1] As of February 2024, AB-103 is in phase 3 clinical trials for treatment of alopecia. [1] It has been in this stage of development since at least April 2019, but there have been no more recent updates on its development since then. [1] The chemical structure of AB-103 does not yet appear to have been disclosed. [1]

See also

References

  1. 1 2 3 4 5 6 7 8 "AB 103". AdisInsight. 27 February 2024. Retrieved 23 October 2025.
  2. ↑ Goren A, Naccarato T (September 2018). "Minoxidil in the treatment of androgenetic alopecia". Dermatologic Therapy. 31 (5) e12686. doi:10.1111/dth.12686. PMID   30155952.
  3. ↑ Roberts J, Desai N, McCoy J, Goren A (2014). "Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia". Dermatologic Therapy. 27 (4): 252–254. doi:10.1111/dth.12130. PMID   24773771.
  4. ↑ Goren A, Shapiro J, Roberts J, McCoy J, Desai N, Zarrab Z, et al. (2015). "Clinical utility and validity of minoxidil response testing in androgenetic alopecia". Dermatologic Therapy. 28 (1): 13–16. doi:10.1111/dth.12164. PMID   25112173.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.